Most With AD, MCI Would Have Been Excluded From Aducanumab Clinical Trials
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.